Nexletol
Payments companies reported to CMS as associated with Nexletol. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Nexletol, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Nexletol
These are the largest totals companies reported as associated with Nexletol. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $100,573.19 |
| John Isaac | Houston, TX | Interventional Cardiology | $56,961.76 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $44,962.84 |
| Narendra Singh | Johns Creek, GA | Cardiovascular Disease | $42,135.11 |
| Denzil Moraes | Baton Rouge, LA | Interventional Cardiology | $34,398.05 |
| James Underberg | New York, NY | Internal Medicine | $31,973.39 |
| Dharmesh Patel | Southaven, MS | Cardiovascular Disease | $31,632.08 |
| William Cromwell | Raleigh, NC | Family Medicine | $28,167.44 |
| Dean Karalis | Philadelphia, PA | Cardiovascular Disease | $27,790.52 |
| Brett Nowlan | Bloomfield, CT | Cardiovascular Disease | $25,104.98 |
Prescribed Nexletol?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.